Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kiadis Pharma Receives Regulatory Approval from Health Canada

Published: Thursday, February 28, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Company has received No Objection Letter for its new clinical study with ATIR™.

Kiadis Pharma B.V. has announced that it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™.

This study will be a Phase II international multi-center study with clinical sites in Canada and Belgium.

Up to 23 patients will be treated in this study to corroborate and extend the safety and efficacy results from Kiadis Pharma‘s previous Phase I/II clinical study with ATIR™.

The coordinating investigator for the study will be Denis-Claude Roy, MD, professor of medicine at the University of Montreal. ATIR™ is a cell-based product designed to enable stem cell transplantations from mismatched (haploidentical) family donors.

“We are very happy that after having received approval from the Research Ethics Board of the Maisonneuve-Rosemont Hospital, we have now also gained approval from Health Canada and can commence with our new clinical study in Canada”, commented Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma.

Ruediger continued, “This study will be an important step forward in developing ATIR™ as an innovative therapeutic option for severely diseased blood cancer patients. Today, many of these patients die because a matched stem cell donor cannot be found.”

Dr. Denis-Claude Roy added: “We are excited that we can start this Phase II clinical study with ATIR™ in which we will treat blood cancer patients for whom a matched donor is not available for a standard transplantation procedure. This study provides these patients with the opportunity to receive a stem cell transplantation from a family member with ATIR™ added as an adjunctive treatment to provide rapid and potent immune protection and minimize post-transplant risks.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™
67% survival demonstrated after 5 years and no transplant related mortalities.
Tuesday, September 17, 2013
Scientific News
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
How to Unlock Inaccessible Genes
An international team of biologists has discovered how specialized enzymes remodel the extremely condensed genetic material in the nucleus of cells in order to control which genes can be used.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!